Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Bristol-Myers Squibb's Opdivo, Yervoy combination cuts risk of progression, death by 42 percent in lung cancer study

firstwordpharmaApril 17, 2018

Tag: Bristol-Myers Squibb , Opdivo

PharmaSources Customer Service